According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Takeda had hoped that Eohilia would be the first-ever treatment for EoE, but that crown was snatched by Sanofi and Regeneron’s injectable antibody Dupixent (dupilumab), which was approved for ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Eosinophilic esophagitis (EoE) is a chronic (long-term) condition affecting the esophagus, the tube that carries food and liquids from the mouth to the stomach. EoE causes symptoms like difficulty ...

First described nearly 20 years ago, eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus characterized by eosinophilic infiltration of the esophageal epithelium. Over 50% of ...

Clinicians should be aware of the latest developments in the diagnosis and management of eosinophilic esophagitis (EoE), including new biologics approved for treatment and the elimination of ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Dupixent achieved over €13 billion in sales, growing 16% in Q4, with strong performance across geographies and indications. Management also noted progress in new indications such as COPD and EoE for ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

The European Commission (EC) approved Dupixent to treat eosinophilic esophagitis in children aged 1 to 11 years, in November 2024. The FDA accepted the resubmission of an sBLA for Dupixent to ...